Periodontitis is the sixth-most prevalent chronic inflammatory disease and gradually devastates tooth-supporting tissue. The complexity of periodontal tissue and the local inflammatory microenvironment poses great challenges to tissue repair. Recently, stem cells have been considered a promising strategy to treat tissue damage and inflammation because of their remarkable properties, including stemness, proliferation, migration, multilineage differentiation, and immunomodulation. Several varieties of stem cells can potentially be applied to periodontal regeneration, including dental mesenchymal stem cells (DMSCs), nonodontogenic stem cells, and induced pluripotent stem cells (iPSCs). In particular, these stem cells possess extensive immunoregulatory capacities. In periodontitis, these cells can exert anti-inflammatory effects and regenerate the periodontium. Stem cells derived from infected tissue possess typical stem cell characteristics with lower immunogenicity and immunosuppression. Several studies have demonstrated that these cells can also regenerate the periodontium. Furthermore, the interaction of stem cells with the surrounding infected microenvironment is critical to periodontal tissue repair. Though the immunomodulatory capabilities of stem cells are not entirely clarified, they show promise for therapeutic application in periodontitis. Here, we summarize the potential of stem cells for periodontium regeneration in periodontitis and focus on their characteristics and immunomodulatory properties as well as challenges and perspectives.

1. Background

Periodontitis is a chronic inflammatory condition that gradually devastates tooth-supporting tissue, which is comprised of the periodontal ligament (PDL), gingiva, and alveolar bone. The severe form of periodontitis, which impacts 743 million around the world, is the sixth-most prevalent chronic disease [1, 2]. Periodontitis is not only the main reason for tooth loss in adults but is also related to a variety of chronic diseases (i.e., diabetes, obesity, osteoporosis, arthritis, depression, cardiovascular disease, and Alzheimer’s disease) [3–5].

Conventional therapies focus on utilizing natural and synthetic materials to fill defects of periodontal tissue, but these substitutes do not result in the actual restoration of the original physical structure and function of the tissue [6]. Due to the complexity of periodontal tissue, it is still a challenge to regenerate the periodontium. Tissue engineering approaches for regenerative dentistry consist of stem cells in the oral cavity, cytoskeleton, and growth factors. Stem cells exhibit highly promising therapeutic potential in periodontal regeneration owing to their self-renewal property and the plasticity of their potential to differentiate [7]. DMSCs, nonodontogenic stem cells, and iPSCs can be applied to periodontal tissue regeneration. Given the remarkable properties and versatility of stem cells, they are considered to be an efficient approach to regenerate periodontal tissue [8–10]. In addition, stem cells play a crucial role in immunosuppressive and anti-inflammatory functions [11]. In periodontitis, stem
cells can be delivered to a site of infection and function as critical players to control inflammation and the immune response, achieving a regenerative process [12].

Here, we briefly summarize the potential of stem cells for periodontium regeneration, mainly focusing on their characteristics and immunomodulatory properties as well as the challenges and perspectives for their application.

2. Pathological Mechanism of Periodontitis

Uncovering the mechanisms of inflammatory responses in periodontitis will facilitate the application of stem cells to treat this disease [13]. Periodontal tissue homeostasis is dependent on the balance between host immune defenses and microbial attacks [14]. Once the dysbiotic microbial community subverts a susceptible host, an inflammatory response is generated [15]. This process is mediated by the immune system of the host, which triggers the breakdown of tooth-supporting structures, resulting in the initiation of periodontitis (Figure 1).

2.1. Microbial Dysbiosis: The Causative Agent of Periodontitis.

The dysbiotic microbial community consists of anaerobic bacterial genera, including Proteobacteria, Firmicutes, Spirochaetes, Synergistetes, and Bacteroidetes [16]. The subgingival microenvironment affords opportunities for the microbial community due to the enrichment of inflammatory mediators. The dysbiotic microbial community subverts host immune responses by enhancing their nutrient acquisition and evasion strategies in the inflammatory milieu. The dysbiotic oral microbiota display synergistic interactions that can cause reciprocal proteomic and transcriptional responses to reinforce nutrient acquisition [17, 18]. The dysbiotic oral microbiota procure nutrients from destructive inflammatory tissue, including heme-containing composites and degraded collagen peptides [19]. These periodontal bacteria can improve their fitness by regulating the communication with the host immune response. For example, these bacteria escape neutrophil-mediated assault and protect themselves from complement. As a result, periodontal tissue breakdown is increased by neutrophil-mediated responses due to the inability of the neutrophil to control the dysbiotic microbial attack [20].

2.2. Host Susceptibility to Periodontitis.

Host susceptibility to periodontitis not only governs the transition from microbial synergy to dysbiosis but also determines the development of inflammation and the progression of irreversible tissue destruction [21, 22]. The progression and severity of periodontitis rely on host-related factors, including immuno-regulatory dysregulation, immunodeficiencies, systemic diseases related to periodontitis (such as diabetes, cardiovascular disease, obesity, osteoporosis, arthritis, depression, and Alzheimer’s disease), risk factors affecting the host’s immune system (such as smoking, stress, ageing, and microbial factors), and regenerative responses [23, 24]. Defects or dysregulation of the host immune response leads to an inability to suppress dysbiotic microbial communities and the resultant pathogenesis. The susceptible host immune response is subverted by dysbiotic microbiota, leading to the formation of a self-perpetuating pathogenic cycle [15].

2.3. Immune Response in Periodontitis.

Once periodontitis is triggered by dysbiotic microbiota, the immune response in periodontitis changes from acute inflammation into the chronic condition and leads to the breakdown of the periodontium [25] (Figure 1).

Dysbiotic microbiota can reinforce their own tolerance to host immune responses by interacting with neutrophils and complement [14]. Neutrophils congregate in the gingival sulcus, while T cells, B cells, and monocytes are recruited. Neutrophils release elastase to degrade membrane proteins in some bacteria, which causes the breakdown of elastin and type IV collagen in the PDL and therefore disintegrates its attachment to the cementum and alveolar bone, leading to the formation of a periodontal pocket [26]. Neutrophils also secrete cytotoxic substances and degradative enzymes (i.e., reactive oxygen species and matrix metalloproteinases) that result in the inflammatory destruction of tissue [27]. In addition, neutrophils release the receptor activator of nuclear factor kappa-B ligand (RANKL), which is necessary for osteoclastogenesis and periodontal bone resorption [28]. Another major source of RANKL is via secretion from B cells and T cells in inflammatory lesions [29]. Specifically, neutrophils mediate the chemotactic recruitment of interleukin (IL-) 17-mediated T helper 17 (Th17) cells through the expression of chemokine ligand (CCL) 2 and CCL20. Meanwhile, chemokine receptor (CCR) 2 and CCR6 are secreted by Th17 cells [30, 31]. Th17 cells are a subset of T cells that promote osteoclastogenesis and act as effective helpers of B cells [32]. The progression of periodontitis is characterized by inflammatory infiltration with large numbers of B cells and plasma cells accompanied by the increasing expression of immune complexes and complement fragments [33]. Specifically, B cells induce the conductive destruction of periodontal tissue which is due to matrix metalloproteinases and inflammatory cytokines secreted by B cells [34].

Macrophages remodel connective tissue by balancing matrix metalloproteinases and their tissue inhibitors. Macrophages also regulate bone homeostasis by mediating osteoblasts and osteoclasts. Moreover, this capacity of polymorphonuclear leukocytes and monocytes is achieved by the secretion of cytokines, including tumor necrosis factor α (TNF-α), adhesion molecules, IL-1β, and IL-6. These factors induce these cells to adhere to the endothelium and to increase the permeability of gingival capillaries and alveolar bone resorption [13, 35].

3. Characteristics, Immunological Properties, and Periodontal Regeneration Potential of Stem Cells

In this section, we review the characteristics as well as the immunological properties of stem cells, including DMSCs, nonodontogenic stem cells, and iPSCs. Specifically, we present stem cells as having potential efficacy for regenerating compromised tissues.
3.1. DMSCs. DMSCs are composed of periodontal ligament stem cells (PDLSCs), dental follicle stem cells (DFSCs), dental pulp-derived stem cells (DPSCs), stem cells from apical papilla (SCAPs), stem cells from exfoliated deciduous teeth (SHEDs), gingival mesenchymal stem cells (GMSCs), and dental socket-derived stem cells (DSSCs) [36, 37] (Figure 2). DMSCs are multipotent stem cells with a self-renewal ability as well as multiple lineage differentiation potentials [38]. More importantly, DMSCs mediate the activity of various immune cells. The immunomodulatory potential of DMSCs mainly relies on inflammatory factors secreted by immune cells.

3.1.1. PDLSCs. The PDL is a connective tissue that connects the tooth root to the surrounding alveolar bone. The PDL originates from the dental follicle and plays a critical role in sustaining tooth homeostasis and providing nutrition. PDLSCs were first derived and identified from adult third molars [39]. PDLSCs have the potential to generate PDLs, alveolar bone, cementum, blood vessels, and peripheral nerves [40]. In addition, these cells also have a self-renewal capacity and high proliferative potential [41]. PDLSCs expressed various types of MSC-related cluster of differentiation (CD) markers, including CD73, CD90, and CD105, and lack expression of hematopoietic markers, such as CD14, CD19, CD34, CD40, CD45, and CD80, and CD86 [42-44]. Human PDLSCs also express antigens such as TRA-1-60, TRA-1-81, sex-determining region Y-box (Sox) 2, alkaline phosphatase (ALP), stage-specific embryonic antigen (SSEA-) 1, SSEA-3, SSEA-4, and reduced expression 1 [6, 45].

Recently, PDLSCs were deemed to be a promising potential cell source for the repair of periodontal defects following periodontitis on account of their immunomodulatory properties (Figure 3). Activated human peripheral blood mononuclear cells (PBMCs) generate interferon- (IFN-) γ, which induces PDLSCs to secrete some soluble factors (i.e., transforming growth factor- (TGF-β), indoleamine 2,3-dioxygenase-1 (IDO-1), and hepatocyte growth factor (HGF)) that, in turn, partially decrease the proliferation of PBMCs [46]. Upregulated proliferation and downregulated apoptosis of neutrophils constitute another innate immune response mediated by PDLSCs [47]. PDLSCs also greatly inhibit T cell proliferation by reducing the secretion of major histocompatibility complex glycoprotein1b (GP1b) and prostaglandin E2 (PGE2) from dendritic cells (DCs) [48]. Additionally, PDLSCs improve the activity and proliferation of anti-inflammatory Treg cells and suppress proinflammatory Th1/Th2/Th17 cells [49]. In addition to these cells, the mechanism of immunosuppression is mediated by PDLSCs through the inhibition of B cell proliferation, migration, and differentiation. These properties of PDLSCs are achieved via stimulating the expression of programmed cell death protein 1 (PD-1) and its ligand (PD-L1) [50]. PDLSCs enhance the polarization of the anti-inflammatory phenotype (M2 phenotype) by stimulating Arginase- (Arg-) 1, CD163, and IL-10 and inhibiting TNF-α [47].

Currently, both the animal experiments and clinical trials demonstrate that PDLSCs can regenerate periodontal defects. Studies have reported that delivery of PDLSCs to periodontal defects in rat models improves periodontal regeneration by generating PDLs, cementum-like tissue, and new bone without inflammation [51]. More importantly, PDLSCs achieve periodontal regeneration without adverse effects. In a miniature swine periodontitis model, transplantation of an allogeneic PDLSC sheet achieved the regeneration of the periodontium and cured periodontitis through immunosuppressive effects and low immunogenicity [52]. A clinical study exhibited that autologous PDLSC transplantation possessed the advantages of stability and effectiveness during the long-term follow-up of patients with periodontitis.
suggesting that PDLSCs may be an innovative approach to treat periodontitis [46].

3.1.2. DFSCs. DFSCs are responsible for periodontium formation by migrating around the tooth germ and differentiating into PDLs, osteoblasts, and cementoblasts [53]. Surface markers of DFSCs contain CD13, CD44, CD73, CD105, CD56, CD271, human leukocyte antigen- (HLA-) ABC, STRO-1, and NOTCH-1. Among them, STRO-1 and CD44 are common surface markers that are used to identify DFSCs [54].
The immunosuppressive properties of DFSCs are dependent on TLRs. In periodontitis, *P. gingivalis* and *F. nucleatum* activate the expression of TLR2 and TLR4 on the membrane of DFSCs and then trigger DFSCs to inhibit the proliferation of peripheral blood mononuclear cells (PBMCs) [55]. Moreover, DFSCs can upregulate the secretion of the anti-inflammatory cytokine IL-10 and simultaneously downregulate the levels of the proinflammatory cytokines IL-4, IL-8, and IFN-γ, thereby damaging bacterial adherence and internalization [56]. DFSCs exert anti-inflammatory effects and suppress bone degradation by mediating the phagocytic activity, chemotaxis, and NET formation of neutrophils and inducing macrophage polarization into the M2 phenotype [57].

Several animal experiments have proven that DFSCs possess the capacity to repair periodontal defects. In a canine model of periodontal defects, the potential of DFSCs to repair periodontal defects was proven via implantation of autologous DFSCs into defects, inducing the generation of new PDLs, alveolar bone, and cementum [36]. In another study, ectopic transplantation of DFSCs from human-impacted third molars into nude mice generated the cementum-PDL complex [58].

3.1.3. DPSCs. DPSCs were the first characterized mesenchymal stem cells derived from the dental pulp in 2002. These cells possess the potential to differentiate into osteogenic, adipogenic, chondrogenic, and neural cells and show high expression of surface markers of MSCs [59].

DPSCs possess the ability to mediate both innate and adaptive immune responses by interacting with T cells, B cells, macrophages, and natural killer (NK) cells [60]. DPSCs exert anti-inflammatory and immunosuppressive effects by suppressing the proliferation of activated T cells as well as triggering apoptotic programmed cell death [61]. DPSCs also inhibit immunoglobulin production of B cells and IL-17 by increasing the secretion of IFN-γ [62]. The inhibitory effect of DPSCs on the proliferation of PBMCs is achieved by generating TGF and stimulating the mitogen-activated protein kinase (MAPK) signaling pathway [63]. DPSCs exert an anti-inflammatory function in two ways. On the one hand, DPSCs inhibit macrophages from secreting TNF-α by an IDO-dependent pathway. On the other hand, DPSCs initiate macrophage M2 polarization [64]. Induction of DPSC differentiation enhances the inhibitory effects of DPSCs on NK cell-mediated lysis and cytotoxicity.

In fact, Park and colleagues showed that DPSCs hardly repaired periodontal defects on account of their limited capacity to form a cementum-like structure, while PDLSCs regenerated the periodontium with new bone, cementum, and Sharpey’s fibers [36]. As the function of DPSCs on pulp repair, there is little research about immunomodulatory properties of DPSCs in PDL tissue. Consequently, the present evidence indicates that DPSCs may not be an appropriate source for periodontal tissue engineering.

3.1.4. SCAPs. SCAPs were first isolated from human apical papilla tissue of immature permanent teeth in 2006 [65]. Similar to other MSCs, SCAPs show a self-renewal capacity, high proliferative potential, and low immunogenicity as well as multilineage differentiation. STRO-1, CD24, and CD146 are widely expressed in SCAPs and are considered to be surface markers of SCAPs [66]. SCAPs can inhibit T cell proliferation by a mechanism independent of apoptosis [67]. It has also been reported that transplanting SCAPs into a periodontitis site significantly ameliorates the periodontitis parameters of periodontal tissue 12 weeks after transplantation [68]. All of these results suggest SCAPs may be a promising cell source for repairing the periodontium in regenerative dentistry.

3.1.5. SHEDs. SHEDs were first characterized and isolated from the human dental pulp of exfoliated deciduous teeth by Miura. SHEDs show the ability to regenerate bone and dentin-like tissue, with a high osteoinductive ability and proliferation rate [62].

SHEDs show immunomodulatory characteristics via mediating T cell activation, maturation, and differentiation. Moreover, downregulation of Th17 cells and upregulation of regulatory T cells (Tregs) are additional immunosuppressive effects of SHEDs [69]. Furthermore, SHEDs can suppress DCs from secreting the inflammatory cytokines IL-2, IFN-γ, and TNF-α and can facilitate DCs to generate the anti-inflammatory factor IL-10 [70]. SHEDs induce polarization of bone marrow-derived macrophages towards M2 polarization, which contributes to the regeneration of the periodontium and anti-inflammatory effects in periodontal tissues [71].

In an experimental periodontitis model, delivery of SHEDs into periodontal tissues led to a reduction of cytokine expression, osteoclast differentiation, and gum bleeding as well as promoted the formation of new attachments of PDL and alveolar bone. These results suggest that SHEDs contribute to the improvement of periodontal regeneration and the decrease of periodontal tissue inflammation [72].

3.1.6. GMSCs. The epithelium and connective tissue make up the human gingiva, which is considered to be an essential constituent of the periodontium that exerts remarkable effects on periodontal regeneration and immunity and is notable for its wound healing properties without scaring. GMSCs were derived and identified from the lamina propria of gingival tissue in 2009 [73]. Based on their remarkable self-renewal, multilineage differentiation, and regenerative abilities, GMSCs are expected to be a suitable cell source in periodontal tissue engineering.

Recently, the easy accessibility and prominent immunomodulatory properties of GMSCs have led to more attention on the use of cellular therapy [74]. GMSC-induced immunomodulation represents a promising perspective in therapy of periodontal tissue inflammation via interaction with inflammatory cells and cytokines [74]. GMSCs communicate with the inflammatory environment through the expression of TLRs 1, 2, 3, 4, 5, 6, 7, and 10, which affect the immunomodulatory properties of GMSCs [75]. Human GMSCs show the capacity to facilitate the polarization of macrophages to the M2 phenotype; meanwhile, they inhibit the activation of M1 macrophages by producing PGE2, IL-6, and IL-10 [76]. Furthermore, GMSCs significantly reduce the activation and
maturation of DCs by a PGE2-related mechanism that suppresses the antigen presentation ability of DCs and weakens the inflammatory response [77]. Human GMSCs also reduce the proliferation and differentiation of Th1/Th2/Th17 cells. GMSCs have an inhibitory function on PHA-dependent T cell proliferation and activation by upregulating immunosuppressive factors, such as IDO and IL-10 [78].

A study reported that GMSCs mixed with an IL-1RA-hydrogel synthetic extracellular matrix, when delivered into a periodontitis model, led to an obvious improvement of regenerating PDLs, cementum, and alveolar bone [74]. In a dog model, the transplantation of GFP-labelled GMSCs into furcation defects obviously improved the regeneration of damaged periodontal tissues [79].

3.1.7. DSSCs. Recent studies have shown that dental sockets can be a potential source for periodontal regeneration. DSSCs have the potential to form colonies and can differentiate into osteoblasts, adipocytes, and chondrocytes [80]. Compared with BMSCs, colony formation, proliferation, and motility of DSSCs are stronger. DSSCs can positively regulate the proliferation and differentiation of Th1/Th2/Th17 cells. DSSCs have the potential to form colonies and can differentiate into osteoblasts, adipocytes, and chondrocytes [81].

Nakajima et al. reported that the transplantation of autologous DSSCs mixed with β-TCP/PGA into one-wall periodontal defects regenerated a new periodontium with PDL-like and cementum-like tissues and alveolar bone [80]. There are few studies on DSSCs, so more preclinical investigations are required to clarify the roles of DSSCs in tissue regeneration and immune regulation.

3.2. Nonodontogenic Stem Cells. Nonodontogenic stem cells are composed of bone marrow stromal stem cells (BMSCs) and adipose tissue-derived stem cells (ASCs).

3.2.1. BMSCs. BMSCs can differentiate into osteoblasts, chondrocytes, adipocytes, and muscle cells [82]. BMSCs are sorted by surface markers of octamer-binding transcription factor-(Oct-) 4, CD73, CD90, CD105, CD146, STRO-1, and Nanog and do not express HLA-DR, CD14, CD34, or CD45. BMSCs have the potential to regenerate periodontal defects by generating alveolar bone, Sharpey’s fibers, and cementum [83]. BMSCs migrate into PDLs, alveolar bone, blood vessels, and cementum and differentiate into osteoblasts and fibroblasts after local or systemic transplantation [84].

Aside from regenerating destroyed tissues in periodontitis, BMSCs also play a crucial role in anti-inflammation and immunosuppressive function [85]. BMSCs mediate the survival and proliferation of T lymphocytes for the regulation of immunomodulation [86]. BMSCs inhibit inflammatory cytokines, including IL-1 and TNF-α, which indicates that the use of BMSCs for the treatment of chronic periodontitis might be feasible [85]. In a clinical study, the combined use of autologous BMSCs and platelet-rich plasma to treat periodontal defects shows obvious tissue regeneration effects [87]. Although a significant improvement in periodontal parameters has been observed, more clinical research is needed to reveal the function of BMSCs and their ability to regulate inflammation and immunity to better target them for the treatment of periodontitis.

3.2.2. ASCs. The characteristics of ASCs are similar to those of BMSCs, such as expression of the markers STRO-1, CD29, CD44, CD71, CD90, and CD105 and the lack of expression of hematopoietic cell markers CD31, CD34, and CD45 [88]. ASCs can differentiate into osteoblast, adipocytes, chondrocytes, myogenic, and neurogenic cells. Compared to BMSCs, ASCs are superior because of their easier harvesting process and because of their fewer notable donor site complications [89]. More importantly, ASCs mixed with cytokines TNF-α, IFN-γ, and IL-6 promote the expression of immune suppressive factors, including GBP4 and IL-1RA [90].

Preclinical studies have demonstrated that ASCs are potential candidate cells for the regeneration of periodontal destruction. ASCs can secrete growth factors, such as insulin-like growth factor binding protein-6, which facilitates the differentiation of ASCs into the periodontium [91]. Allogeneic ASCs were transplanted in a microminipig model of periodontal tissue defects and led to the generation of new PDL-like fibers, alveolar bone, and the cementum in defect sites [90].

3.3. Induced Pluripotent Stem Cells (iPSCs). The formation of iPSCs can be achieved by reprogramming somatic cells with the transcriptional markers Oct4, Sox2, Krüppel-like factor 4, and Myc [92]. iPSCs express special pluripotent markers, including TRA160, TRA180, MSC-heat shock protein 90, CD73, CD90, CD105, CD146, and CD106 [93]. iPSCs are pluripotent stem cells with the potential to generate iPSC-derived MSCs (iPSC-MSCs) and to differentiate into multilineage cells [94]. As a promising candidate, iPSCs not only have the potential to regenerate bone, cartilage, brain, heart, and liver tissue but also can be applied for inflammatory tissue regeneration in periodontitis [95]. Stem cells from dental tissue, including PDLs, buccal mucosa fibroblasts, gingival, apical papilla, and the dental pulp, have advantages for the generation of iPSCs [96].

Moreover, iPSC-MSCs can inhibit Th1/Th2/Th17 cells and upregulate the expression of Treg cells, suppressing the production of leukocytes and alveolar bone resorption [97, 98]. iPSCs are a potential cell source for the clinical prevention and treatment of periodontitis. Duan et al. showed that transplantation of iPSCs to a scaffold with enamel-derived factors significantly increased PDL, alveolar bone, and cementum formation in a mouse periodontal defect model compared with iPSC-empty groups [99]. Another study reported that iPSCs could inhibit inflammation and decrease alveolar bone resorption in a rat model of periodontitis. In addition, Hynes et al. stated that iPSC-MSCs could repair periodontal tissue defects and control inflammation while lessening alveolar bone destruction [100].

4. Interaction of Stem Cells with the Inflammatory Milieu of the Periodontium

What happens to the stem cells in periodontitis and how they interact with periodontal inflammation are crucial for the
application of stem cells into periodontal regeneration [101]. For instance, the interaction of stem cells and immune cells in the inflammatory milieu may be completely different from that in a healthy state with altered regenerative processes and immunomodulatory properties [102]. Thus, it is essential to understand the properties of stem cells derived from inflammatory tissue as well as the inflammatory responses and immunomodulation properties of stem cells in an inflamed microenvironment.

4.1. Stem Cells from Inflamed Tissue. Inflamed stem cells exhibit characteristics including maintenance of stemness, formation of colonies, a higher proliferation rate, multilineage differentiation potential, and lower immunogenicity and immunosuppression [102].

In this section, we introduce the properties and immunomodulation of DMSCs in inflammatory periodontal sites. Among stem cells, DMSCs derived from infected tissue possess the significant advantages of being easily accessible and having fewer ethical complications [103]. Compared with other DMSCs, PDLSCs are considered to be an ideal cell source for periodontal regeneration [104], but there are still problems with obtaining enough PDLSCs from healthy donor sources. PDLSCs derived from inflamed periodontal sites are considered inflammatory periodontal ligament stem cells (iPDLSCs). Compared to PDLSCs, iPDLSCs have higher proliferative and migratory capacities. However, iPDLSCs exhibit lower osteogenic differentiation because of alterations of the osteogenesis-related signaling pathway, such as the Wnt/β-catenin, noncanonical Wnt/Ca2+, p38-MAPK, and NF-κB signaling pathways [105, 106]. More importantly, iPDLSCs also have reduced immunosuppressive properties and less efficiently suppress T cell proliferation, PBMC proliferation, and Th1 differentiation in contrast to cells from healthy tissue [107]. High levels of IFN-γ, TNF-α, IL-2, and IDO and low expression of IL-10 are also characteristic of iPDLSCs [108]. A study reporting on the transplantation of collagen sponges combined with iPDLSs isolated from inflamed human periodontal tissue into immunodeficient nude rats led to the formation of new PDL-like tissue, bone, and collagen fibers. Although complete regeneration was not achieved, the repair effect of iPDLSCs on periodontal defects was similar to that of PDLSCs from healthy periodontal tissues [51]. Compared with normal DPSCs, DPSCs derived from infected tissue (iDPSCs) show similar surface marker expression, proliferation properties, and multilineage differentiation potential [109, 110]. DPSCs derived from infected human tissue were layered onto β-tricalcium phosphate and grafted into periodontal defects in the root furcation. The outcome revealed new formation of alveolar bone [111]. These results have important implications for achieving periodontium regeneration with DMSCs obtained from inflammatory tissues in the future [112]. It may be a promising strategy to cultivate or even genetically modify DMSCs obtained from infected tissue, avoiding the destruction of the healthy periodontium while implanting DMSCs into inflamed periodontium tissue to achieve regeneration [113, 114].

However, there are still various issues that should be taken into account before translational application. For example, the source of inflamed stem cells, the inflammatory status, and the experimental design are confounding variables that will affect the quality and quantity of stem cells [115]. Furthermore, the inclusion criteria as well as the procedure for the isolation and transplantation of the inflamed stem cells should be established and standardized to further explore and verify the long-term effects of inflamed stem cells via in vivo and in vitro experiments [57, 116, 117].

4.2. Effect of the Infected Microenvironment on Stem Cells. The interaction of stem cells with the surrounding infected microenvironment could affect the mechanism of periodontal tissue repair and the regeneration outcome [102]. Transplantation of stem cells into periodontal defects is usually performed in an inflamed periodontal milieu, and the immunomodulatory capacity of stem cells is determined by diverse inflammatory cytokines. Therefore, understanding the effect of inflammatory cytokines on stem cells is critical to optimize and implement stem cell-mediated clinical approaches [118, 119].

Various inflammatory cytokines can specifically mediate the immunomodulatory activity of stem cells [120]. Among various inflammatory mediators, TNF-α, IL-1β, IL-6, and IFN-γ are the most effective proinflammatory cytokines during periodontitis [121]. The proinflammatory cytokines TNF-α, IL-1α, IL-1β, and IFN-γ exert critical effects by mitigating the immunosuppressive capacities of stem cells [122]. Low levels of IFN-γ improve antigen-presenting functions of stem cells and thus reduce their lysis. In contrast, high levels would reverse their antigen-presenting functions and show the opposite effect [123, 124].

Several studies have demonstrated the effects of an infected microenvironment on DMSCs. For example, P. gingivalis-LPS significantly enhanced cellular proliferation of DMSCs [125]. In addition, coculturing PDLSCs with IL-1β/TNF-α could enhance the proliferation rate of PDLSCs [126]. The surface markers of DMSCs, such as PDLSCs and GMSCs, do not change within the IL-1β/TNF-α-infused microenvironment. However, the effect may be compromised or may even lead to stem cell apoptosis when the IL-1β/TNF-α stimulus surpasses a certain level. The differentiation potential of DMSCs could be mediated by proinflammatory cytokines and microbial pathogens [127]. Specifically, P. gingivalis-LPS and E.coli-LPS inhibit PDLSCs’ osteoblastic differentiation [125, 128]. IL-1β/TNF-α are responsible for reducing the osteogenesis of PDLSCs by stimulating the canonical Wnt/β-catenin pathway and inhibiting the noncanonical Wnt/Ca2+ pathway in the local periodontal milieu [106].

Other stem cells also exert important effects on the infected microenvironment. An increasing number of studies have shown that IFN-γ is required for BMSCs to exert their immunosuppressive effect on T lymphocyte proliferation. Additionally, both LPS and IFN-γ can induce the secretion of functional IDO and IL-10 by BMSCs [129]. LPS-induced proliferation of PBMCs could be inhibited by BMSCs [73]. Transplantation of BMSCs into LPS-stimulated models could inhibit the production of inflammatory cytokines and ameliorate inflammatory tissue destruction [130]. The interaction of ASCs with the inflammatory microenvironment is necessary to achieve tissue regeneration. In response
to inflammatory cytokines, ASCs facilitate the anti-inflammatory and immunosuppressive potential through the induction of polarization of macrophages to the M2 phenotype [131]. When stimulated with TNF-α and IFN-γ, ASCs significantly increased their immunomodulatory capacities [132].

5. Conclusion, Future Clinical Application, and Challenges

To date, application of extracellular matrix scaffolds, bone grafts, and growth factors achieve only limited regeneration of intrabony defects [133]. In the past few years, developing data have indicated that stem cells have great potential in periodontitis due to the positive inflammatory-regenerative effects of these cells in the inflamed microenvironment [36, 134]. These stem cells have remarkable properties and versatility due to their stemness, proliferation, migration, and multilineage differentiation abilities and their immunosuppressive and anti-inflammatory functions in a local inflamed microenvironment [118, 135, 136].

The immunoregulatory effects of stem cells make them a promising therapy for periodontitis. Although several reports have indicated that the stem cells mentioned above can be delivered into infectious sites and function as critical players in the control of inflammation and the regulation of immune responses to achieve regeneration in models of periodontitis, the immunomodulatory capabilities of these cells have not entirely been elucidated [137, 138]. Moreover, evidence of stem cell-mediated immunomodulation is limited both in vitro and in vivo. It is very complicated to recreate extremely polluted surroundings in animal models because human periodontal lesions are filled with granulation tissue, calculus, pathogenic biofilms, and plaque [139]. Furthermore, there are various differences in the mechanisms of stem cell-mediated immunomodulation between humans and animals [140]. The quality and quantity of stem cells can be modulated by numerous factors, including the sources of stem cells and the experimental design [141]. The inclusion of subjects and procedures for the isolation and transplantation of stem cells can influence the outcome of regeneration and immunomodulation.

Therefore, inclusion criteria as well as a standard procedure for the isolation and transplantation of the stem cells should be established to further explore the long-term effects of stem cells. Standard animal models of periodontitis should be constructed to mimic human periodontal lesions. Selection of suitable biomaterial scaffolds and the appropriate combination with growth factors for stem cells may improve their periodontal regeneration and immunosuppression functions. More importantly, preclinical studies and clinical trials are critical to understand the mechanism of stem cell-mediated immunomodulation.

---

**Table 1: The characteristic of different stem cells could be potentially applied to periodontal regeneration.**

| Stem cell | Multipotent differentiation | Immunomodulatory properties | Clinical trials |
|-----------|-----------------------------|----------------------------|----------------|
| **DMSCs** | Osteoblast, adipocytes, chondrocytes, cementoblast, and neurogenic cells | Inhibition of PBMCs, T cells, B cells, promotion of Treg cells, neutrophils, and M2 phenotype macrophage | NCT01357785 NCT01082822 |
| PDLSCs | Osteoblast, adipocytes, chondrocytes, cementoblast, and neurogenic cells | Inhibition of PBMCs, promotion of Treg cells, neutrophils, and M2 phenotype macrophage | NCT03386877 NCT02523651 |
| DFSCs | Osteoblast, adipocytes, chondrocytes, cementoblast, and dentin-like cell | Inhibition of PBMCs, T cells, B cells, and NK cells; promotion of Treg cells, neutrophils, and M2 phenotype macrophage | |
| DPSCs | Osteoblast, adipocytes, odontoblast, osteogenic cells, cardiomyocyte, and hepatocyte | Inhibition of PBMCs, T cells, B cells, and NK cells; promotion of Treg cells, neutrophils, and M2 phenotype macrophage | |
| SCAPs | Osteoblast, adipocytes, odontoblast, osteogenic cells, and hepatocyte | Low immunogenicity; inhibition of T cells | |
| SHEDs | Osteoblast, adipocytes, chondrocytes, and neurogenic cells | Inhibition of Th17 cells; promotion of Treg cells and M2 phenotype macrophage | |
| GMSCs | Osteoblast, adipocytes, chondrocytes, and neurogenic cells | Inhibition of M1 macrophages, Th1/Th2/Th17 cells, and DCs; promotion of Treg cells and M2 phenotype macrophage | NCT03137979 |
| DSSCs | Osteoblast, adipocytes, and chondrocytes | No report | |
| **Nonodontogenic stem cells** | | | |
| BMSCs | Osteoblast, adipocytes, and chondrocytes | Inhibition of T lymphocyte survival and proliferation; secretion of IL-1 and TNF-α | NCT02449005 |
| ASCs | Osteoblast, adipocytes, chondrocytes, myogenic cells, and neurogenic cells | Promotion of immune suppressive factors GBP4 and IL-1RA | NCT04270006 |
| iPSCs | Osteoblast, adipocytes, chondrocytes, myogenic cells, neurogenic cells, cementoblast, cardiomyocyte, and dentin-like cell | Inhibition of Th1/Th2/Th17 cells; promotion of Treg cells | |

The clinical trial data have been extracted from https://clinicaltrials.gov.
mediated immunomodulation in the inflammatory milieu to pave the way for applying stem cells to periodontal tissue engineering (Table 1).

Abbreviations

DMSCs: Dental mesenchymal stem cells  
iPSCs: Induced pluripotent stem cells  
iDMSCs: DMSCs derived from infected tissue  
PDL: Periodontal ligament  
TLRs: Toll-like receptors  
RANKL: Receptor activator of nuclear factor kappa-B ligand  
IL: Interleukin  
Th17: T helper 17  
CCL: Chemokine ligand  
CCR: Chemokine receptor  
TNF-α: Tumor necrosis factor α  
PDLCs: Periodontal ligament stem cells  
BMSCs: Bone marrow stromal stem cells  
DCs: Dendritic cells  
Tregs: Regulatory T cells  
MAPK: Mitogen-activated protein kinase  
NK cells: Natural killer cells  
IDO-1: Indoleamine 2,3-dioxygenase-1  
HGF: Hepatocyte growth factor  
TNF-αβ: Tumor necrosis factor αβ  
RANKL: Receptor activator of nuclear factor kappa-B ligand  
NK cells: Natural killer cells  
MAPK: Mitogen-activated protein kinase  
Tregs: Regulatory T cells  
MPS: Mononuclear phagocytes  
BMMCs: Bone marrow mononuclear cells  
IFN: Interferon  
TGF-β: Transforming growth factor-β  
IDO-1: Indoleamine 2,3-dioxygenase-1  
HGF: Hepatocyte growth factor  
PD-1: Programmed cell death protein 1  
Arg: Arginase  
HLAG: Human leukocyte antigen  
NK cells: Natural killer cells  
MAPK: Mitogen-activated protein kinase  
Tregs: Regulatory T cells  
DCs: Dendritic cells  
BMSCs: Bone marrow stromal stem cells  
ASCs: Adipose tissue-derived stem cells  
Oct: Octamer-binding transcription factor  
HLAG: Human leukocyte antigen  
iPDLSCs: Inflammatory periodontal ligament stem cells.

Data Availability

The human clinical trials data included in this review are available at https://clinicaltrials.gov/.

Disclosure

The authors state that this manuscript includes original unpublished work.

Conflicts of Interest

The authors declare no conflicts of interest.

Authors’ Contributions

All authors have made substantial, direct, and intellectual contributions to the work. At the same time, all authors participated in designing the study and drafting and writing the manuscript as well as approving it for submission.

Acknowledgments

This work was supported by grants from the National Natural Science Foundation of China (NSFC, 81600842) and Science Foundation of Health Commission of Sichuan Province (17PJ547).

References

[1] N. J. Kassebaum, E. Bernabé, M. Dahiya, B. Bhandari, C. J. L. Murray, and W. Marcenes, “Global burden of severe periodontitis in 1990–2010: a systematic review and meta-regression,” Journal of Dental Research, vol. 93, no. 11, pp. 1045–1053, 2014.
[2] M. A. Peres, B. Daly, C. C. Guarinizo-Herreño, H. Benzian, and R. G. Watt, “Oral diseases: a global public health challenge – authors’ reply,” The Lancet, vol. 395, no. 10219, pp. 186-187, 2020.
[3] R. J. Genco and T. E. Van Dyke, “Reducing the risk of CVD in patients with periodontitis,” Nature Reviews Cardiology, vol. 7, no. 9, pp. 479-480, 2010.
[4] G. Hajishengallis, “Periodontitis: from microbial immune subversion to systemic inflammation,” Nature Reviews Immunology, vol. 15, no. 1, pp. 30–44, 2015.
[5] E. Lalla and P. N. Papapanou, “Diabetes mellitus and periodontitis: a tale of two common interrelated diseases,” Nature Reviews Endocrinology, vol. 7, no. 12, pp. 738–748, 2011.
[6] W. Zhu and M. Liang, “Periodontal ligament stem cells: current status, concerns, and future prospects,” Stem Cells International, vol. 2015, Article ID 972313, 11 pages, 2015.
[7] P. Bianco, P. G. Robey, I. Saggio, and M. Riminucci, “Mesenchymal” stem cells in human bone marrow (skeletal stem cells): a critical discussion of their nature, identity, and significance in incurable skeletal disease,” Human Gene Therapy, vol. 21, no. 9, pp. 1057–1066, 2010.
[8] E. P. Chalisserry, S. Y. Nam, S. H. Park, and S. Anil, “Therapeutic potential of dental stem cells,” Journal of Tissue Engineering, vol. 8, Article ID 204731417702531, 2016.
[9] Y. C. Guo, M. Y. Wang, S. W. Zhang et al., “Ubiquitin-specific protease USP34 controls osteogenic differentiation and bone formation by regulating BMP2 signaling,” The EMBO Journal, vol. 37, no. 20, 2018.
[10] W. Liu, L. Zhou, C. Zhou et al., “GDF11 decreases bone mass by stimulating osteoclastogenesis and inhibiting osteoblast differentiation,” Nature Communications, vol. 7, no. 1, article 12794, 2016.
[11] B. Hernández-Monjaraz, E. Santiago-Osorio, A. Monroy-García, E. Ledesma-Martinez, and V. Mendoza-Nuñez, “Mesenchymal stem cells of dental origin for inducing tissue
regeneration in periodontitis: a mini-review,” *International Journal of Molecular Sciences*, vol. 19, no. 4, p. 944, 2018.

[12] X. Fu, L. Jin, P. Ma, Z. Fan, and S. Wang, “Allogenic stem cells from deciduous teeth in treatment for periodontitis in miniature swine,” *Journal of Periodontology*, vol. 85, no. 6, pp. 845–851, 2014.

[13] P. J. Ford, J. Gamonal, and G. J. Seymour, “Immunological differences and similarities between chronic periodontitis and aggressive periodontitis,” *Periodontology 2000*, vol. 53, no. 1, pp. 111–123, 2010.

[14] K. Barth, D. G. Remick, and C. A. Genco, “Disruption of immune regulation by microbial pathogens and resulting chronic inflammation,” *Journal of Cellular Physiology*, vol. 228, no. 7, pp. 1413–1422, 2013.

[15] G. Hajishengallis, “Immunomicrobial pathogenesis of periodontitis: keystones, pathobionts, and host response,” *Trends in Immunology*, vol. 35, no. 1, pp. 3–11, 2014.

[16] Z. L. Deng, S. P. Szafra, K. S. Jarek, S. Bluju, and I. Wagner-Döbler, “Dysbiosis in chronic periodontitis: key microbial players and interactions with the human host,” *Scientific Reports*, vol. 7, no. 1, article 3703, 2017.

[17] A. Mira, A. Simon-Soro, and M. A. Curtis, “Role of microbial communities in the pathogenesis of periodontal diseases and caries,” *Journal of Clinical Periodontology*, vol. 44, Supplement 18, pp. S23–S38, 2017.

[18] F. A. Roberts and B. P. Darveau, “Microbial protection and virulence in periodontal tissue as a function of polymicrobial communities: symbiosis and dysbiosis,” *Periodontology 2000*, vol. 69, no. 1, pp. 18–27, 2015.

[19] D. Baraniya, M. Naginyte, T. Chen et al., “Dysbiosis in chronic periodontitis: key microbial players and interactions with the human host,” *Scientific Reports*, vol. 7, no. 1, article 3703, 2017.

[20] D. K. Gaudilliere, A. Culos, K. Diebali et al., “Systemic immunologic consequences of chronic periodontitis,” *Journal of Dental Research*, vol. 98, no. 9, pp. 985–993, 2019.

[21] K. S. Kornman, “Contemporary approaches for identifying individual risk for periodontitis,” *Periodontology 2000*, vol. 78, no. 1, pp. 12–29, 2018.

[22] M. L. Laine, W. Crielaard, and B. G. Loos, “Genetic susceptibility to periodontitis,” *Periodontology 2000*, vol. 58, no. 1, pp. 37–68, 2012.

[23] A. Stabholz, W. A. Sokolne, and L. Sharip, “Genetic and environmental risk factors for chronic periodontitis and aggressive periodontitis,” *Periodontology 2000*, vol. 53, no. 1, pp. 138–153, 2010.

[24] M. A. Reynolds, “Modifiable risk factors in periodontitis: at the intersection of aging and disease,” *Periodontology 2000*, vol. 64, no. 1, pp. 7–19, 2014.

[25] G. Nussbaum and L. Sharip, “How has neutrophil research improved our understanding of periodontal pathogenesis?,” *Journal of Clinical Periodontology*, vol. 38, Supplement 11, pp. 49–59, 2011.

[26] H. Alfaqry, E. Malle, C. N. Koyani, P. J. Pussinen, and T. Sorsa, “Neutrophil proteolytic activation cascades: a possible mechanistic link between chronic periodontitis and coronary heart disease,” *Innate Immunity*, vol. 22, no. 1, pp. 85–99, 2015.

[27] A. Mantovani, M. A. Cassatella, C. Costantini, and S. Jaillon, “Neutrophils in the activation and regulation of innate and adaptive immunity,” *Nature Reviews Immunology*, vol. 11, no. 8, pp. 519–531, 2011.

[28] A. Chakravarti, M. A. Raquill, P. Tessier, and P. E. Poubelle, “Surface RANKL of Toll-like receptor 4-stimulated human neutrophils activates osteoclastic bone resorption,” *Blood*, vol. 114, no. 8, pp. 1633–1644, 2009.

[29] M. Kajiya, G. Giro, M. A. Taubman, X. Han, M. P. A. Mayer, and T. Kawai, “Role of periodontal pathogenic bacteria in RANKL-mediated bone destruction in periodontal disease,” *Journal of Oral Microbiology*, vol. 2, no. 1, 2010.

[30] M. Pelletier, L. Maggi, A. Micheletti et al., “Evidence for a cross-talk between human neutrophils and Th17 cells,” *Blood*, vol. 115, no. 2, pp. 335–343, 2010.

[31] P. Miossec and J. K. Kolls, “Targeting IL-17 and Th17 cells in chronic inflammation,” *Nature Reviews Drug Discovery*, vol. 11, no. 10, pp. 763–776, 2012.

[32] D. T. Graves, T. Oates, and G. P. Garlet, “Review of osteoimmunology and the host response in endodontic and periodontal lesions,” *Journal of Oral Microbiology*, vol. 3, no. 1, 2011.

[33] S. Kurgan and A. Kantarci, “Molecular basis for immunohistochemical and inflammatory changes during progression of gingivitis to periodontitis,” *Periodontology 2000*, vol. 76, no. 1, pp. 51–67, 2018.

[34] T. Berglundh, M. Donati, and N. Zittmann, “B cells in periodontitis: friends or enemies?,” *Periodontology 2000*, vol. 45, no. 1, pp. 51–66, 2007.

[35] J. Meyle and I. Chappelle, “Molecular aspects of the pathogenesis of periodontitis,” *Periodontology 2000*, vol. 69, no. 1, pp. 7–17, 2015.

[36] J. Y. Park, S. H. Jeon, and P. H. Choung, “Efficacy of periodontal stem cell transplantation in the treatment of advanced periodontitis,” *Cell Transplantation*, vol. 20, no. 2, pp. 271–286, 2011.

[37] C.-Y. C. Huang, D. Pelaez, J. D. Bendala, F. Garcia-Godoy, and H. S. Cheung, “Plasticity of stem cells derived from adult periodontal ligament,” *Regenerative Medicine*, vol. 4, no. 6, pp. 809–821, 2009.

[38] M. Wang, Q. Yuan, and L. Xie, “Mesenchymal stem cell-based immunomodulation: properties and clinical application,” *Stem Cells International*, vol. 2018, Article ID 3057624, 12 pages, 2018.

[39] B. M. Seo, M. Miura, S. Gronthos et al., “Investigation of multipotent postnatal stem cells from human periodontal ligament,” *The Lancet*, vol. 364, no. 9429, pp. 149–155, 2004.

[40] A. Tomokiyo, S. Yoshida, H. Sugii, and H. Maeda, “Detection, characterization, and clinical application of mesenchymal stem cells in periodontal ligament tissue,” *Stem Cells International*, vol. 2018, Article ID 5450768, 9 pages, 2018.

[41] C. Martinez, P. C. Smith, J. P. Rodriguez, and V. Palma, “Sonic hedgehog stimulates proliferation of human periodontal ligament stem cells,” *Journal of Dental Research*, vol. 90, no. 4, pp. 483–488, 2011.

[42] N. Kawanabe, S. Murata, K. Murakami et al., “Isolation of multipotent stem cells in human periodontal ligament using stage-specific embryonic antigen-4,” *Differentiation*, vol. 79, no. 2, pp. 74–83, 2010.

[43] K. Iwasaki, M. Komaki, N. Yokoyama et al., “Periodontal ligament stem cells possess the characteristics of pericytes,” *Journal of Periodontology*, vol. 84, no. 10, pp. 1425–1433, 2013.
[44] L. Wang, H. Shen, W. Zheng et al., “Characterization of stem cells from alveolar periodontal ligament,” Tissue Engineering Part A, vol. 17, no. 7-8, pp. 1015–1026, 2011.

[45] J. Xiong, D. Menicanin, P. S. Zilm, V. Marino, P. M. Bartold, and S. Grnthos, “Investigation of the cell surface proteome of human periodontal ligament stem cells,” Stem Cells International, vol. 2016, Article ID 1947157, 13 pages, 2016.

[46] O. Andrukhov, J. S. A. Hong, O. Andrukhova, A. Blufstein, A. Moritz, and X. Rausch-Fan, “Response of human periodontal ligament stem cells to IFN-γ and TLR-agonists,” Scientific Reports, vol. 7, no. 1, p. 12856, 2017.

[47] J. Liu, B. Chen, J. Bao, Y. Zhang, L. Lei, and F. Yan, “Macrophage polarization in periodontal ligament stem cells enhanced periodontal regeneration,” Stem Cell Research & Therapy, vol. 10, no. 1, p. 320, 2019.

[48] C. Shin, M. Kim, J. A. Han et al., “Human periodontal ligament stem cells suppress T-cell proliferation via down-regulation of non-classical major histocompatibility complex-like glycoprotein CD1b on dendritic cells,” Journal of Periodontal Research, vol. 52, no. 1, pp. 135–146, 2017.

[49] J. Ng, K. Hynes, G. White et al., “Immunomodulatory properties of induced pluripotent stem cell-derived mesenchymal cells,” Journal of Cellular Biochemistry, vol. 117, no. 12, pp. 2844–2853, 2016.

[50] O. Liu, J. Xu, G. Ding et al., “Periodontal ligament stem cells regulate B lymphocyte function via programmed cell death protein 1,” Stem Cells, vol. 31, no. 7, pp. 1371–1382, 2013.

[51] J. Qiu, X. Wang, H. Zhou et al., “Enhancement of periodontal tissue regeneration by conditioned media from gingiva-derived or periodontal ligament-derived mesenchymal stem cells: a comparative study in rats,” Stem Cell Research & Therapy, vol. 11, no. 1, p. 42, 2020.

[52] G. Ding, Y. Liu, W. Wang et al., “Allogeneic periodontal ligament stem cell therapy for periodontitis in swine,” Stem Cells, vol. 28, no. 10, pp. 1829–1838, 2010.

[53] H. Yang, J. Li, Y. Hu et al., “Treated dentin matrix particles combined with dental follicle cell sheet stimulate periodontal regeneration,” Dental Materials, vol. 35, no. 9, pp. 1238–1253, 2019.

[54] T. Zhou, J. Pan, P. Wu et al., “Dental follicle cells: roles in development and beyond,” Stem Cells International, vol. 2019, Article ID 9159605, 17 pages, 2019.

[55] J. Liu, L. Wang, W. Liu, Q. Li, Z. Jin, and Y. Jin, “Dental follicle cells rescue the regenerative capacity of periodontal ligament stem cells in an inflammatory microenvironment,” PLoS One, vol. 9, no. 10, article e108752, 2014.

[56] K. Chatchivassieiou, C. A. Lux, G. Steinhoeff, and H. Lang, “Dental follicle progenitor cells responses to Porphyromonas gingivalis LPS,” Journal of Cellular and Molecular Medicine, vol. 17, no. 6, pp. 766–773, 2013.

[57] X. Chen, B. Yang, J. Tian et al., “Dental follicle stem cells ameliorate lipopolysaccharide-induced inflammation by secreting TGF-β3 and TSP-1 to elicit macrophage M2 polarization,” Cellular Physiology and Biochemistry, vol. 51, no. 5, pp. 2290–2308, 2018.

[58] W. Guo, L. Chen, K. Gong, B. Ding, Y. Duan, and Y. Jin, “Heterogeneous dental follicle cells and the regeneration of complex periodontal tissues,” Tissue Engineering Part A, vol. 18, no. 5-6, pp. 459–470, 2012.

[59] T. L. Fernandes, J. P. Cortez de SantAnna, I. Frisene et al., “Systematic review of human dental pulp stem cells for cartilage regeneration,” Tissue Engineering Part B, Reviews, vol. 26, no. 1, pp. 1–12, 2020.

[60] L. Ji, L. Bao, Z. Gu et al., “Comparison of immunomodulatory properties of exosomes derived from bone marrow mesenchymal stem cells and dental pulp stem cells,” Immunologic Research, vol. 67, no. 4–5, pp. 432–442, 2019.

[61] A. T. Ozdemir, R. B. Ozgul Ozdemir, C. Kirmaz et al., “The paracrine immunomodulatory interactions between the human dental pulp derived mesenchymal stem cells and CD4 T cell subsets,” Cellular Immunology, vol. 310, pp. 108–115, 2016.

[62] M. Maioli, V. Basoli, S. Santaniello et al., “Osteogenesis from dental pulp derived stem cells: a novel conditioned medium including melatonin within a mixture of hyaluronic, butyric, and retinoic acids,” Stem Cells International, vol. 2016, Article ID 2056416, 8 pages, 2016.

[63] S. Tomic, J. Djokic, S. Vasilijic et al., “Immunomodulatory properties of mesenchymal stem cells derived from dental pulp and dental follicle are susceptible to activation by toll-like receptor agonists,” Stem Cells and Development, vol. 20, no. 4, pp. 695–708, 2011.

[64] S. Lee, Q. Z. Zhang, B. Karabucak, and A. D. Le, “DPSCs from inflamed pulp modulate macrophage function via the TNF-α/IDO axis,” Journal of Dental Research, vol. 95, no. 11, pp. 1274–1281, 2016.

[65] W. Sonoyama, Y. Liu, T. Yamaza et al., “Characterization of the apical papilla and its residing stem cells from human immature permanent teeth: a pilot study,” Journal of Endodontia, vol. 34, no. 2, pp. 166–171, 2008.

[66] J. Kang, W. Fan, Q. Deng, H. He, and F. Huang, “Stem cells from the apical papilla: a promising source for stem cell-based therapy,” BioMed Research International, vol. 2019, Article ID 6104738, 8 pages, 2019.

[67] G. Ding, Y. Liu, Y. An et al., “Suppression of T cell proliferation by root apical papilla stem cells in vitro,” Cells, Tissues, Organs, vol. 191, no. 5, pp. 357–364, 2010.

[68] G. Li, N. Han, X. Zhang et al., “Local injection of allogeneic stem cells from apical papilla enhanced periodontal tissue regeneration in minipig model of periodontitis,” BioMed Research International, vol. 2018, Article ID 3960798, 8 pages, 2018.

[69] S. Yildirim, N. Zibandeh, D. Genc, E. M. Ozcan, K. Goker, and T. Akkok, “The comparison of the immunologic properties of stem cells isolated from human exfoliated deciduous teeth, dental pulp, and dental follicles,” Stem Cells International, vol. 2016, Article ID 4682875, 15 pages, 2016.

[70] F. de Sá Silva, R. N. Ramos, D. C. de Almeida et al., “Mesenchymal stem cells derived from human exfoliated deciduous teeth (SHEDs) induce immune modulatory profile in monocyte-derived dendritic cells,” PLoS One, vol. 9, no. 5, article e98050, 2014.

[71] Z. Li, C. M. Jiang, S. An et al., “Immunomodulatory properties of dental tissue-derived mesenchymal stem cells,” Oral Diseases, vol. 20, no. 1, pp. 25–34, 2014.

[72] X. Gao, Z. Shen, M. Guan et al., “Immunomodulatory role of stem cells from human exfoliated deciduous teeth on periodontal regeneration,” Tissue Engineering. Part A, vol. 24, no. 17-18, pp. 1341–1353, 2018.

[73] Q. Zhang, S. Shi, Y. Liu et al., “Mesenchymal stem cells derived from human gingiva are capable of immunomodulatory functions and ameliorate inflammation-related tissue...
destruction in experimental colitis,” *Journal of Immunology*, vol. 183, no. 12, pp. 7787–7798, 2009.

[74] K. M. Fawzy El-Sayed and C. E. Dorfer, “Gingival mesenchymal stem/progenitor cells: a unique tissue engineering gem,” *Stem Cells International*, vol. 2016, Article ID 7154327, 16 pages, 2016.

[75] K. Fawzy-El-Sayed, M. Mehmehar, S. Adam-Klages, D. Kabelitz, and C. Dorfer, “TIR expression profile of human gingival margin-derived stem progenitor cells,” *Medicina Oral, Patología Oral y Cirugía Bucal*, vol. 21, no. 1, pp. e30–e38, 2016.

[76] Q. Z. Zhang, A. L. Nguyen, W. H. Yu, and A. D. le, “Human oral mucosa and gingiva: a unique reservoir for mesenchymal stem cells,” *Journal of Dental Research*, vol. 91, no. 11, pp. 1011–1018, 2012.

[77] W. R. Su, Q. Z. Zhang, S. H. Shi, A. L. Nguyen, and A. D. le, “Human gingiva-derived mesenchymal stromal cells attenuate contact hypersensitivity via prostaglandin E2-dependent mechanisms,” *Stem Cells*, vol. 29, no. 11, pp. 1849–1860, 2011.

[78] C. M. Jiang, J. Liu, J. Y. Zhao et al., “Effects of hypoxia on the immunomodulatory properties of human gingiva-derived mesenchymal stem cells,” *Journal of Dental Research*, vol. 94, no. 1, pp. 69–77, 2014.

[79] X. Yu, S. Ge, S. Chen et al., “Human gingiva-derived mesenchymal stromal cells contribute to periodontal regeneration in beagle dogs,” *Cells, Tissues, Organs*, vol. 198, no. 6, pp. 428–437, 2014.

[80] R. Nakajima, M. Ono, E. S. Hara et al., “Mesenchymal stem/progenitor cell isolation from tooth extraction sockets,” *Journal of Dental Research*, vol. 93, no. 11, pp. 1133–1140, 2014.

[81] J. Luo, J. Xu, J. Cai, L. Wang, Q. Sun, and P. Yang, “The in vitro and in vivo osteogenic capability of the extraction socket-derived early healing tissue,” *Journal of Periodontology*, vol. 87, no. 9, pp. 1057–1066, 2016.

[82] N. Baryawno, D. Przybylski, M. S. Kowalczyk et al., “A cellular taxonomy of the bone marrow stroma in homeostasis and leukemia,” *Cell*, vol. 177, no. 7, pp. 1915–1932.e16, 2019, e16.

[83] M. Paknejad, M. B. Esalminejad, B. Ghaedi et al., “Isolation and assessment of mesenchymal stem cells derived from bone marrow: histologic and histomorphometric study in a canine periodontal defect,” *The Journal of Oral Implantology*, vol. 41, no. 3, pp. 284–291, 2015.

[84] N. Hasegawa, H. Kawaguchi, A. Hirachi et al., “Behavior of transplanted bone marrow-derived mesenchymal stem cells in periodontal defects,” *Journal of Periodontology*, vol. 77, no. 6, pp. 1003–1007, 2006.

[85] J. Du, Z. Shan, P. Ma, S. Wang, and Z. Fan, “Allogeneic bone marrow mesenchymal stem cell transplantation for periodontal regeneration,” *Journal of Dental Research*, vol. 93, no. 2, pp. 183–188, 2013.

[86] L. Xiao, Y. Zhou, L. Zhu et al., “SPHK1-1PR1-RANKL axis regulates the interactions between macrophages and BMSCs in inflammatory bone loss,” *Journal of Bone and Mineral Research*, vol. 33, no. 6, pp. 1090–1104, 2018.

[87] Y. Yamada, S. Nakamura, K. Ito et al., “Injectable bone tissue engineering using expanded mesenchymal stem cells,” *Stem Cells*, vol. 31, no. 3, pp. 572–580, 2013.

[88] L. Xu, Y. Liu, Y. Sun et al., “Tissue source determines the differentiation potentials of mesenchymal stem cells: a comparative study of human mesenchymal stem cells from bone marrow and adipose tissue,” *Stem Cell Research & Therapy*, vol. 8, no. 1, p. 275, 2017.

[89] G. T. Huang, S. Gronthos, and S. Shi, “Mesenchymal stem cells derived from dental tissues vs. those from other sources: their biology and role in regenerative medicine,” *Journal of Dental Research*, vol. 88, no. 9, pp. 792–806, 2009.

[90] V. S. Venkatadha, K. Handa, M. M. Njuguna et al., “Periodontal regeneration by allogeneic transplantation of adipose tissue derived multi-lineage progenitor stem cells in vivo,” *Scientific Reports*, vol. 9, no. 1, p. 921, 2019.

[91] K. Sawada, M. Takedachi, S. Yamamoto et al., “Trophic factors from adipose tissue-derived multi-lineage progenitor cells promote cytodifferentiation of periodontal ligament cells,” *Biochemical and Biophysical Research Communications*, vol. 464, no. 1, pp. 299–305, 2015.

[92] K. Takahashi and S. Yamanaka, “Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors,” *Cell*, vol. 126, no. 4, pp. 663–676, 2006.

[93] H. Yang, R. M. Aprecio, X. Zhou et al., “Therapeutic effect of TSG-6 engineered iPSC-derived MSCs on experimental periodontitis in rats: a pilot study,” *PLoS One*, vol. 9, no. 6, article e100285, 2014.

[94] K. Hynes, D. Menichanin, R. Bright et al., “Induced pluripotent stem cells: a new frontier for stem cells in dentistry,” *Journal of Dental Research*, vol. 94, no. 11, pp. 1508–1515, 2015.

[95] A. Revilla, C. González, A. Iriondo et al., “Current advances in the generation of human iPSCs: implications in cell-based regenerative medicine,” *Journal of Tissue Engineering and Regenerative Medicine*, vol. 10, no. 11, pp. 893–907, 2016.

[96] N. Malhotra, “Induced pluripotent stem (iPS) cells in dentistry: a review,” *International Journal of Stem Cells*, vol. 9, no. 2, pp. 176–185, 2016.

[97] K. Hynes, R. Bright, V. Marino et al., “Potential of iPSC-derived mesenchymal stromal cells for treating periodontal disease,” *Stem Cells International*, vol. 2018, Article ID 2601945, 12 pages, 2018.

[98] P. P. Cheng, X. C. Liu, P. F. Ma et al., “iPSC-MSCs combined with low-dose rapamycin induced islet allograft tolerance through suppressing Th1 and enhancing regulatory T-cell differentiation,” *Stem Cells and Development*, vol. 24, no. 15, pp. 1793–1804, 2015.

[99] X. Duan, Q. Tu, J. Zhang et al., “Application of induced pluripotent stem (iPS) cells in periodontal tissue regeneration,” *Journal of Cellular Physiology*, vol. 226, no. 1, pp. 150–157, 2011.

[100] K. Hynes, D. Menicinhan, J. Han et al., “Mesenchymal stem cells from iPSCs facilitate periodontal regeneration,” *Journal of Dental Research*, vol. 92, no. 9, pp. 833–839, 2013.

[101] K. M. Fawzy El-Sayed, M. Elahmady, Z. Adawi et al., “The periodontal stem/progenitor cell inflammatory-regenerative cross talk: a new perspective,” *Journal of Periodontal Research*, vol. 54, no. 2, pp. 81–94, 2018.

[102] C. Zheng, J. Chen, S. Liu, and Y. Jin, “Stem cell-based bone and dental regeneration: a view of microenvironmental modulation,” *International Journal of Oral Science*, vol. 11, no. 3, p. 23, 2019.

[103] S. Guo, J. Kang, B. Ji et al., “Periodontal-derived mesenchymal cell sheets promote periodontal regeneration in
inflammatory microenvironment,” *Tissue Engineering Part A*, vol. 23, no. 13-14, pp. 585–596, 2017.

[104] Q. Zhai, Z. Dong, W. Wang, B. Li, and Y. Jin, “Dental stem cell and dental tissue regeneration,” *Frontiers in Medicine*, vol. 13, no. 2, pp. 152–159, 2019.

[105] H. N. Tang, Y. Xia, Y. Yu, R. X. Wu, L. N. Gao, and F. M. Chen, “Stem cells derived from ‘inflamed’ and healthy periodontal ligament tissues and their sheet functionalities: a patient-matched comparison,” *Journal of Clinical Periodontology*, vol. 43, no. 1, pp. 72–84, 2016.

[106] N. Liu, S. Shi, M. Deng et al., “High levels of β-catenin signaling reduce osteogenic differentiation of stem cells in inflammatory microenvironments through inhibition of the noncanonical Wnt pathway,” *Journal of Bone and Mineral Research*, vol. 26, no. 9, pp. 2082–2095, 2011.

[107] D. Liu, J. Xu, O. Liu et al., “Mesenchymal stem cells derived from inflamed periodontal ligaments exhibit impaired immunomodulation,” *Journal of Clinical Periodontology*, vol. 39, no. 12, pp. 1174–1182, 2012.

[108] C. Li, X. Wang, J. Tan, T. Wang, and Q. Wang, “The immunomodulatory properties of periodontal ligament stem cells isolated from inflamed periodontal granulation,” *Cells, Tissues, Organs*, vol. 199, no. 4, pp. 256–265, 2015.

[109] D. J. Alongi, T. Yamaza, Y. Song et al., “Stem/progenitor cells from inflamed human dental pulp retain tissue regeneration potential,” *Regenerative Medicine*, vol. 5, no. 4, pp. 617–631, 2010.

[110] A. Attar, M. B. Eslamnejad, M. S. Tavangar et al., “Dental pulp polyps contain stem cells comparable to the normal dental pulps,” *Journal of Clinical and Experimental Dentistry*, vol. 6, no. 1, pp. e53–e59, 2014.

[111] Y. Li, X. Nan, T. Y. Zhong, T. Li, and A. Li, “Treatment of periodontal bone defects with stem cells from inflammatory dental pulp tissues in miniature swine,” *Tissue Engineering and Regenerative Medicine*, vol. 16, no. 2, pp. 191–200, 2019.

[112] Y. D. Cho, K. H. Kim, H. M. Ryoo, Y. M. Lee, Y. Ku, and Y. J. Seol, “Recent advances of useful cell sources in the periodontal regeneration,” *Current Stem Cell Research & Therapy*, vol. 14, no. 1, pp. 3–8, 2019.

[113] K. H. Chien, Y. L. Chang, M. L. Wang et al., “Promoting induced pluripotent stem cell-driven biominaleralization and periodontal regeneration in rats with maxillary–molar defects using injectable BMP-6 hydrogel,” *Scientific Reports*, vol. 8, no. 1, p. 114, 2018.

[114] Y. Tang, L. Liu, P. Wang, D. Chen, Z. Wu, and C. Tang, “Peroxisome promotes migration and osteogenic differentiation of human periodontal ligament mesenchymal stem cells via the Jun amino-terminal kinases (JNK) pathway under inflammatory conditions,” *Cell Proliferation*, vol. 50, no. 6, article e12369, 2017.

[115] O. Androukhov, C. Behm, A. Blufstein, and X. Rausch-Fan, “Immunomodulatory properties of dental tissue-derived mesenchymal stem cells: implication in disease and tissue regeneration,” *World Journal of Stem Cells*, vol. 11, no. 9, pp. 604–617, 2019.

[116] S. Onizuka and T. Iwata, “Application of periodontal ligament-derived multipotent mesenchymal stromal cell sheets for periodontal regeneration,” *International Journal of Molecular Sciences*, vol. 20, no. 11, article 2796, 2019.

[117] J. C. Park, J. M. Kim, I. H. Jung et al., “Isolation and characterization of human periodontal ligament (PDL) stem cells (PDLSCs) from the inflamed PDL tissue: in vitro and in vivo evaluations,” *Journal of Clinical Periodontology*, vol. 38, no. 8, pp. 721–731, 2011.

[118] Y. Zhou, L. Zheng, X. Zhou, J. Li, and X. Xu, “Dental mesenchymal stem cells in inflamed microenvironment: potentials and challenges for regeneration,” *Current Stem Cell Research & Therapy*, vol. 10, no. 5, pp. 412–421, 2015.

[119] L. Hu, Y. Liu, and S. Wang, “Stem cell-based tooth and periodontal regeneration,” *Oral Diseases*, vol. 24, no. 5, pp. 696–705, 2018.

[120] A. F. Stadler, P. D. M. Angst, R. M. Arce, S. C. Gomes, R. V. Oppermann, and C. Susin, “Gingival crevicular fluid levels of cytokines/chemokines in chronic periodontitis: a meta-analysis,” *Journal of Clinical Periodontology*, vol. 43, no. 9, pp. 727–745, 2016.

[121] X. Y. Zheng, C. Y. Mao, H. Qiao et al., “Plumbagin suppresses chronic periodontitis in rats via down-regulation of TNF-α, IL-1β and IL-6 expression,” *Acta Pharmacologica Sinica*, vol. 38, no. 8, pp. 1150–1160, 2017.

[122] D. Whiting, W. O. Chung, J. D. Johnson, and A. Paranjpe, “Characterization of the cellular responses of dental mesenchymal stem cells to the immune system,” *Journal of Endodontia*, vol. 44, no. 7, pp. 1126–1131, 2018.

[123] J. L. Chan, K. C. Tang, A. P. Patel et al., “Antigen-presenting property of mesenchymal stem cells occurs during a narrow window at low levels of interferon-gamma,” *Blood*, vol. 107, no. 12, pp. 4817–4824, 2006.

[124] W. K. Chan, A. S. Y. Lau, J. C. B. Li, H. K. W. Law, Y. L. Lau, and G. C. F. Chan, “MHC expression kinetics and immunogenicity of mesenchymal stromal cells after short-term IFN-γ challenge,” *Experimental Hematology*, vol. 36, no. 11, pp. 1545–1555, 2008.

[125] H. Kato, Y. Taguchi, K. Tominaga, M. Umeda, and A. Tanaka, “Porphyromonas gingivalis LPS inhibits osteoblastic differentiation and promotes pro-inflammatory cytokine production in human periodontal ligament stem cells,” *Archives of Oral Biology*, vol. 59, no. 2, pp. 167–175, 2014.

[126] Y. Liu, L. Wang, T. Kikuiiri et al., “Mesenchymal stem cell-based tissue regeneration is governed by recipient T lymphocytes via IFN-γ and TNF-α,” *Nature Medicine*, vol. 17, no. 12, pp. 1594–1601, 2011.

[127] H. Yang, L. N. Gao, Y. An et al., “Comparison of mesenchymal stem cells derived from gingival tissue and periodontal ligament in different incubation conditions,” *Biomaterials*, vol. 34, no. 29, pp. 7033–7047, 2013.

[128] T. Kukolj, D. Trivanovic, I. O. Djordjevic et al., “Lipopolysaccharide can modify differentiation and immunomodulatory potential of periodontal ligament stem cells via ERK1,2 signaling,” *Journal of Cellular Physiology*, vol. 233, no. 1, pp. 447–462, 2018.

[129] A. Lawitschka, L. Ball, and C. Peters, “Nonpharmacologic treatment of chronic graft-versus-host disease in children and adolescents,” *Biology of Blood and Marrow Transplantation*, vol. 18, no. 1, pp. S74–S81, 2012.

[130] Z. H. Zhang, W. Zhu, H. Z. Ren et al., “Mesenchymal stem cells increase expression of heme oxygenase-1 leading to anti-inflammatory activity in treatment of acute liver failure,” *Stem Cell Research & Therapy*, vol. 8, no. 1, p. 70, 2017.

[131] P. Anderson, L. Souza-Moreira, M. Morell et al., “Adipose-derived mesenchymal stromal cells induce immunomodulatory...
macrophages which protect from experimental colitis and sepsis,” Gut, vol. 62, no. 8, pp. 1131–1141, 2013.

[132] R. Domenis, A. Cifù, S. Quaglia et al., “Pro inflammatory stimuli enhance the immunosuppressive functions of adipose mesenchymal stem cells-derived exosomes,” Scientific Reports, vol. 8, no. 1, article 13325, 2018.

[133] N. Donos, E. Calciolari, N. Brusselaers, M. Goldoni, N. Bostanci, and G. N. Belibasakis, “The adjuctive use of host modulators in non-surgical periodontal therapy. A systematic review of randomized, placebo-controlled clinical studies,” Journal of Clinical Periodontology, 2019.

[134] S. A. Tassi, N. Z. Sergio, M. Y. O. Misawa, and C. C. Villar, “Efficacy of stem cells on periodontal regeneration: systematic review of pre-clinical studies,” Journal of Periodontal Research, vol. 52, no. 5, pp. 793–812, 2017.

[135] Y. Wu, L. Xie, M. Wang et al., “Mettl3-mediated m6A RNA methylation regulates the fate of bone marrow mesenchymal stem cells and osteoporosis,” Nature Communications, vol. 9, no. 1, article 4772, 2018.

[136] P. Bindal, T. S. Ramasamy, N. H. A. Kasim, N. Gnanasegaran, and W. L. Chai, “Immune responses of human dental pulp stem cells in lipopolysaccharide-induced microenvironment,” Cell Biology International, vol. 42, no. 7, pp. 832–840, 2018.

[137] J. H. Kim, C. H. Jo, H. R. Kim, and Y. I. Hwang, “Comparison of immunological characteristics of mesenchymal stem cells from the periodontal ligament, umbilical cord, and adipose tissue,” Stem Cells International, vol. 2018, Article ID 8429042, 12 pages, 2018.

[138] G. Sriram, V. P. Natu, I. Islam et al., “Innate immune response of human embryonic stem cell-derived fibroblasts and mesenchymal stem cells to periodontopathogens,” Stem Cells International, vol. 2016, Article ID 8905365, 15 pages, 2016.

[139] L. Fiorillo, G. Cervino, A. Herford et al., “Interferon crevicular fluid profile and correlation with periodontal disease and wound healing: a systematic review of recent data,” International Journal of Molecular Sciences, vol. 19, no. 7, article 1908, 2018.

[140] T. Vigo, C. Procaccini, G. Ferrara et al., “IFN-γ orchestrates mesenchymal stem cell plasticity through the signal transducer and activator of transcription 1 and 3 and mammalian target of rapamycin pathways,” The Journal of Allergy and Clinical Immunology, vol. 139, no. 5, pp. 1667–1676, 2017.

[141] M. Kibschull, S. J. Lye, S. T. Okino, and H. Sarras, “Quantitative large scale gene expression profiling from human stem cell culture micro samples using multiplex pre-amplification,” Systems Biology in Reproductive Medicine, vol. 62, no. 1, pp. 84–91, 2015.